Amarin (AMRN) Announces Patent Allowance Related to Vascapa

February 12, 2013 6:51 AM EST Send to a Friend
Amarin Corporation plc (Nasdaq: AMRN)announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice of Allowance for U.S. Patent Application Serial Number 13/614,129. This application includes claims intended to protect the Vascepa® (icosapent ethyl) indication approved by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results.

A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2030. After issuance, Amarin plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

The claims in this allowed application cover a method of use relating to Vascepa's MARINE indication. Specifically, the allowed independent claim covers use of a pharmaceutical composition comprising 2000 mg to about 5000 mg of icosapent ethyl, or EPA, independent of DHA content, present in one or more capsules, to reduce triglycerides by at least 20%.

This application is part of an expanding patent portfolio for Amarin with 18 patent applications now either issued or allowed with the USPTO and over 30 additional applications pending in the United States. Amarin is also pursuing patent applications related to Vascepa in multiple jurisdictions outside the United States.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News

Add Your Comment